Oral Nanotherapeutics

TRIOZAN™ Nanocarriers have the potential to protect drug molecules (small molecules and biologics) from gastric digestion and improve the oral absorption through the small intestine by helping to cross efficiently the mucosal barrier (mucoadhesiveness and opening of epithelial tight junctions).


Once in the circulation, TRIOZAN™ Nanocarriers may allow decreasing the uptake by the Mononuclear Phagocytic System (MPS) due to the prevention of opsonization of the nanocarriers. The nanocarriers will circulate within the blood system for a longer period of time allowing to reach the target quickly and safely.

Oral Delivery